Azarga: Clinical Trials

13 trials of Azarga, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 1 terminated. 12 Phase 4, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 412Completed 11, Terminated 1
Phase 31Completed 1

Follow Azarga: new trials by email Literature Review of Azarga trials Research Report on Azarga

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil
Brinzolamide/timolol maleate fixed combination - Glaucoma
Phase 4TerminatedAlcon Research92012-03-012013-10-21
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America
Brinzolamide/timolol maleate fixed combination - Glaucoma
Phase 4CompletedAlcon Research502011-12-012015-08-07
Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada
Brinzolamide 1% / timolol 0.5% maleate fixed combination - Glaucoma, Ocular Hypertension
Phase 4CompletedAlcon Research572011-09-012014-07-01
Patient Preference Comparison of AZARGA Versus COSOPT
Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension, Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution - Open-Angle Glaucoma, Ocular Hypertension
Phase 4CompletedAlcon Research1122011-09-012014-02-10
AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure
Brinzolamide 1% and timolol 0.5% fixed combination eye drops - Glaucoma
Phase 4CompletedAlcon Research742011-05-012013-05-01
Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy
Brinzolamide 1% / timolol 0.5% Fixed Combination, Habitual prostaglandin monotherapy - Glaucoma, Ocular Hypertension
Phase 4CompletedAlcon Research472011-03-012014-05-20
Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension
Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension, Brinzolamide 1% ophthalmic suspension, Timolol 0.5% ophthalmic solution - Open-Angle Glaucoma, Ocular Hypertension
Phase 3CompletedAlcon Research3282010-11-012014-04-10
Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Glaucoma
Brinzolamide/Timolol Maleate Fixed Combination (AZARGA), Dorzolamide/timolol Maleate Fixed Combination (COSOPT) - Glaucoma
Phase 4CompletedAlcon Research1202010-09-012016-11-21
Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular Hypertension
Azarga (brinzolamide 1% / timolol 0.5%), Cosopt (dorzolamide 2% / timolol 0.5%) - Glaucoma, Ocular Hypertension
Phase 4CompletedAlcon Research702010-04-012015-07-29
ELAZOP Switching Study in Korea
Elazop (Azarga) - Open Angle Glaucoma
Phase 4CompletedAlcon Research962010-03-012012-12-17
24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol
Brimonidine/timolol fixed combination drops added to travoprost, Brinzolamide/timolol fixed combination drops added to travoprost - Glaucoma
Phase 4CompletedAristotle University Of Thessaloniki512009-08-012020-12-17
Efficacy and Safety of Adding Azarga to Prostaglandin Monotherapy
Brinzolamide/Timolol Maleate Fixed Combination (AZARGA) - Glaucoma
Phase 4CompletedAlcon Research472009-07-012016-11-21
Circadian Ocular Perfusion Pressure and Ocular Blood Flow
Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension, Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution - Glaucoma
Phase 4CompletedAlcon Research352009-02-012013-03-22

Conditions studied

Glaucoma (12)  ·  Glaucoma, Open-Angle (9)  ·  Ocular Hypertension (9)

Sponsors

Alcon Research (12)  ·  Aristotle University Of Thessaloniki (1)

Countries

United States (2)  ·  Argentina (1)  ·  Brazil (1)  ·  Canada (1)  ·  Germany (1)  ·  South Korea (1)

Top investigators

Abayomi Ogundele, PharmD (1)  ·  Anastasios G Konstas, MD, PhD (1)  ·  Danyel C. Carr, MS, CCRA (1)  ·  Doug Hubatsch (1)  ·  Doug Hubatsch, M.Sc. (1)  ·  Mandy Ye, MS (1)  ·  Severine Durier, Pharm. D (1)  ·  Severine Durier, Pharm.D (1)

Results publications

PMID 22205835